The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer

Author

  • H. Olsson
  • Å Borg
  • S. B. Ewers
  • M. Fernö
  • T. Möller
  • J. Ranstam

Summary, in English

In a population-based group of women, consecutively diagnosed, with premenopausal breast cancer there was a significant correlation between tumour size and plasma prolactin (r=0.30;P<0.004). The concentration of estrogen receptor was negatively correlated to tumour size (r=-0.17;P<0.09). There were no substantial correlations between tumour size and progesterone receptor, plasma progesterone or estradiol. Adjustments for menstrual cycle day and age did not alter the above findings. The ratio of plasma prolactin and estrogen receptor was significantly greater (P<0.037) for the group of the patients that had started using oral contraceptives before the age of 20 as compared with the other patients. Consequently, the tumour size was significantly greater in the group of early users (P<0.003). The findings indicate that breast tumours developing in previous early users of oral contraceptives have a low estrogen receptor concentration, while these patients have plasma prolactin. The tumour size is greater in early users indicating a poorer prognosis than other women with breast cancer. As early use of oral contraceptives increases, breast cancer risk and a high ratio of plasma prolactin and estrogen receptor concentration of the primary tumour characterize early oral contraceptive users the ratio may be a valuable marker for the breast cancer risk.

Department/s

  • Tumor microenvironment
  • Breastcancer-genetics

Publishing year

1986-06-01

Language

English

Pages

77-81

Publication/Series

Medical Oncology and Tumor Pharmacotherapy

Volume

3

Issue

2

Document type

Journal article

Publisher

Humana Press

Topic

  • Cancer and Oncology

Keywords

  • Estrogen receptor
  • Marker
  • Oral contraceptive use
  • Plasma prolactin
  • Premenopausal breast cancer
  • Progesterone receptor

Status

Published

ISBN/ISSN/Other

  • ISSN: 0736-0118